Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

Leap Day Boosts February Deal Volume

by | Mar 4, 2016 9:27 pm | Behavioral Health Care, Biotechnology, eHealth, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

It’s Leap Year, which means February was a day longer in 2016. This year, that extra day marked the announcement of seven healthcare transactions, which raised the month’s total to a healthy 113 deals. The services sectors were more active than usual, and accounted for 65% of the total. Usually, the services side makes up about 55% to 60%. Dollar volume was healthy, too, at $27.7 billion. But given the records set in 2015, February’s dollar total ended up 35% below the same month a year ago. The deals may be getting smaller, but they’re still being made. Read More »

2015 Health Care M&A Beats All Records

by | Jan 28, 2016 2:55 pm | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

It’s déjà vu all over again. 2014 was a record-breaker for health care M&A, with 1,317 transactions and spending at an astronomical $387 billion. Then 2015 came and went and, once again, we’re writing about a record-breaking number of transactions, 1,460 currently, and astronomical spending of $563 billion. Read More »

Agenus on a roll in 2015

by | Dec 29, 2015 8:20 am | Biotechnology

Agenus Inc., an immunology company developing novel checkpoint modulators, vaccines and adjuvants to treat cancer, acquired Phoslmmune Inc. last week. Phoslmmune is an immunotherapy company that has discovered a new portfolio of cancer neoantigens. Its equity holders will receive an upfront payment of $2.5 million in cash and $7.4 million in shares of Agenus common stock at closing, plus milestone payments of up to $35 million in cash and/or stock. This acquisition gives Agenus the capacity to expediate the development of new cancer vaccines and other single-agent immuno-oncology approaches, as well as combination therapies. And the deal most likely caps a healthy year for Agenus, which... Read More »

Martin Shkreli, We Hardly Knew Ye

by | Dec 17, 2015 9:45 pm | Biotechnology, Pharmaceuticals

Actually, we know Martin Shkreli, CEO of KaloBios Pharmaceuticals (NASDAQ: KBIO), all too well. The brash young man was arrested by the Federal Bureau of Investigations yesterday in Manhattan, on charges of fraud relating to his days at a hedge. Just weeks before, as then-CEO of privately held Turing Pharmaceuticals, he became the poster child of drug price gougers, having boosted the price of a long-marketed generic drug by 5000%, from $13.50 per pill to $750. The revelations in a New York Times story brought swift recriminations from all sides, including presidential candidates. The most striking note for us, as health care database wonks, is that Shkreli launched his first biotech... Read More »

Big Deal of the Day: Shire Buys Dyax

by | Nov 3, 2015 6:48 pm | Biotechnology, Pharmaceuticals

Shire plc (NASDAQ: SHPG) is on a buying binge in 2015. After agreeing to be acquired by AbbVie (NYSE: ABBV) for $54.7 billion in July 2014, the deal fell apart in October following the Treasury Department’s revised ruling on foreign domiciles. Shire management turned around and acquired rare disease drug maker NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) in January for $5.2 billion, then added prescription drug maker  Meritage Pharma, Inc. in February for $70 million. After a few months digesting those deals, Shire was back on the acquisition trail in August, paying $300 million for Foresight Biotherapeutics Inc., a clincal stage drug development company. Now it’s agreed to pay... Read More »

Q3:15 Health Care Dollars, vs. Q2:15

by | Nov 2, 2015 8:57 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Last week we gave you the breakdown on how the third quarter of 2015 compared with the second quarter and the same quarter a year ago. Here’s how the dollars broke out, versus those quarters. SectorQ3:15Q2:15ChangeQ3:14Change Services Behavioral Health Care$550,000$190,700188%$335,00064% Home Health & Hospice$241,854$0n/a$410,000-41% Hospitals$2,069,865 $2,059,9000.5%$969,800113% Labs, MRI & Dialysis$826,600$1,507,650-45%$324,000155% Long-Term Care$4,175,656$4,141,9300.8%$9,686,200-57% Managed Care$98,000,000$147,00066566%$0n/a Physician Medical Groups$1,600,000$500,000220%$0n/a Rehabilitation $4,300$734,800-99%$163,450-97% Other Services$1,396,474$16,211,644-91%$1,026,40036%... Read More »